Interv Akut Kardiol. 2008;7(1):21-23

Bleeding scale and bleeding complication of the antithrombotic therapy in cardiologic patients

Róbert ©evčík1, Jan Vojáček1,2, Josef Bis1, Hana ©evčíková1, Jaroslav Duąek1, Josef ©»ásek2
1 I. interní klinika Fakultní nemocnice v Hradci Králové
2 Kardiocentrum dospělých, oddělení invazivní kardiologie interní kliniky 2. LF UK a FN Motol, Praha

Antithrombotic drugs are the cornerstone of the cardiovascular medicine. Bleeding is certainly the hottest problem of the chronic antithrombotic therapy. Contemporary bleeding scales do not assess bleeding complications of anticoagulation and/or antiaggregation therapy, because they were primarily designed for trombolysis in pantients with myocardial infarction. The new bleeding score proposal was developed to focus on chronic antithrombotic therapy and their complications. The recent data from many registers shows incorrect dosage of antithrombotic therapy and define risc factors of bleeding.

Keywords: antithrombotic therapy, bleeding scales, risc factors of bleeding

Published: March 27, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©evčík R, Vojáček J, Bis J, ©evčíková H, Duąek J, ©»ásek J. Bleeding scale and bleeding complication of the antithrombotic therapy in cardiologic patients. Interv Akut Kardiol. 2008;7(1):21-23.
Download citation

References

  1. Delaney JA, Opatrny L, Brophy JM et al. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347-351. Go to original source... Go to PubMed...
  2. Khurram Z, Chou E, Minutello R et al. Combination therapy with aspirin, Clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006; 18: 162-164. Go to PubMed...
  3. Webert KE, Cook RJ, Sigouin CS, et al. The risk of bleeding in thrombocytopenic patients with myeloid leukemia. haematologica 2006; 91: 1530-1537. Go to PubMed...
  4. Sabatine MS, McCabe CH, Gibson CM et al. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. American Heart Journal 2005; 149: 227-233. Go to original source... Go to PubMed...
  5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 1993; 329: 673-682. Go to original source... Go to PubMed...
  6. Rao SV, O'Grady K et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 809-816. Go to original source... Go to PubMed...
  7. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982-1988. Go to original source... Go to PubMed...
  8. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials-proposal of a new classification. Am J Cardiol 2007; 99: 288-290. Go to original source... Go to PubMed...
  9. Nelson M. BleedScore proposal - the reader's comment. Am J Cardiol 2007; 100: 560. Go to original source... Go to PubMed...
  10. Alexander KP et al. CRUSADE registry. Circulation. 2006; 114: 1380-1387. Go to original source... Go to PubMed...
  11. Prabhakaran D, Yusuf S, Mehta S et al. Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. Indian Heart J. 2005; 57: 217-225.
  12. Ohman EM. CATCH registry J Thromb Thrombolysis 2005; 19: 11. Go to original source... Go to PubMed...
  13. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002; 325: 828-831. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.